Provided by Tiger Trade Technology Pte. Ltd.

MDB Capital Holdings LLC-A

2.92
-0.0699-2.34%
Post-market: 2.920.00000.00%16:10 EDT
Volume:1K
Turnover:4K
Market Cap:30.48M
PE:-1.38
High:3.23
Open:3.23
Low:2.92
Close:2.99
52wk High:4.80
52wk Low:2.45
Shares:10.44M
Float Shares:4.73M
Volume Ratio:0.79
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1197
EPS(LYR):-2.1197
ROE:-34.74%
ROA:-33.94%
PB:0.54
PE(LYR):-1.38

Loading ...

MDB Capital Holdings Schedules Second-quarter 2026 Update Call Via Zoom Webinar

Reuters
·
Jul 31

Exozymes Prices Registered Direct Offering at USD 18 Per Unit, Raising USD 639,990 Gross

Reuters
·
Jul 02

NASDAQ Trade Halt Volatility Trading Pause at 10:13 Am

Reuters
·
Jul 01

PatentVest report maps muscle-preservation drug programs expanding GLP-1 obesity market opportunity

Reuters
·
Jun 05

MDB Capital set to present at Planet MicroCap Las Vegas conference

Reuters
·
Jun 04

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:25 PM

Reuters
·
May 19

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:28 AM

Reuters
·
May 15

MDB Capital net loss widens to USD 6.74 million in Q1 2026

Reuters
·
May 15

MDB Capital Holdings director Daniel Torpey files initial beneficial ownership statement

Reuters
·
May 09

PatentVest maps triple-agonist obesity drug pipeline, flags emerging patent battle

Reuters
·
May 08

MDB Capital report says retatrutide hits 28.7% weight loss, shifts obesity drug race to IP

Reuters
·
Apr 29

MDB Capital director Terry Jeb Barton Sr. files initial beneficial ownership statement

Reuters
·
Apr 10

MDB Capital Holdings Bets on AI-Fueled Launch Surge

TIPRANKS
·
Apr 06

PatentVest report flags $19B amylin drug deal boom in obesity treatment race

Reuters
·
Apr 01

MDB Capital FY25 net loss widens to $21.3 million; fee income climbs to $4.3 million

Reuters
·
Apr 01

MDB Capital Holdings Provides 2025 Full Year Update and Shareholder Letter

GlobeNewswire
·
Apr 01

MDB Capital Holdings to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time

GlobeNewswire
·
Mar 23

PatentVest completes strategic intellectual property collaboration with Porosome Therapeutics

Reuters
·
Mar 12

Patentvest Announces Strategic Intellectual Property Collaboration With Porosome Therapeutics to Strengthen Platform for Secretory Disorder Therapeutics

THOMSON REUTERS
·
Mar 12

PatentVest Report Maps Oral Small-Molecule GLP-1 Patent Race

Reuters
·
Feb 27